Indication
prevention of chemotherapy-induced myelosuppression
1 clinical trial
2 products
Product
ALRN-6924Clinical trial
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)Status: Terminated, Estimated PCD: 2023-02-22
Product
TAC